NeraCare develops and commercializes molecular diagnostic tests for patients with skin cancer. The tests provide actionable, tumor-specific information for each individual patient. The information is used to make improved treatment decisions, i.e. whether therapy is absolutely necessary or whether a patients` survival estimate is so favourable that it is reasonable to avoid drug therapy and the associated, severe side effects. Through its partnerships with pharmaceutical companies and leading investigators, NeraCare is at the forefront of designing cutting-edge clinical trials to help expand access to drugs for early stage patients. NeraCare`s initial focus is a quantitative RT-PCR-based assay – MELAGENIX (derived from `melanoma` & `genetics`) – which complements conventional risk assessment (i.e. AJCC staging) and helps make individualized, therapeutic decisions for melanoma patients. The intended use is in stage I-III patients.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Globally (various continents)